作者
Panagiotis Baliakas, Sabine Jeromin, Michalis Iskas, Anna Puiggros, Karla Plevova, Florence Nguyen-Khac, Zadie Davis, Gian Matteo Rigolin, Andrea Visentin, Aliki Xochelli, Julio Delgado, Fanny Baran-Marszak, Evangelia Stalika, Pau Abrisqueta, Kristina Durechova, George Papaioannou, Virginie Eclache, Maria Dimou, Theodoros Iliakis, Rosa Collado, Michael Doubek, M Jose Calasanz, Neus Ruiz-Xiville, Carolina Moreno, Marie Jarosova, Alexander C Leeksma, Panayiotis Panayiotidis, Helena Podgornik, Florence Cymbalista, Achilles Anagnostopoulos, Livio Trentin, Niki Stavroyianni, Fred Davi, Paolo Ghia, Arnon P Kater, Antonio Cuneo, Sarka Pospisilova, Blanca Espinet, Anastasia Athanasiadou, David Oscier, Claudia Haferlach, Kostas Stamatopoulos
发表日期
2019/3/14
期刊
Blood
卷号
133
期号
11
页码范围
1205-1216
出版商
American Society of Hematology
简介
Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with ≥5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low …
学术搜索中的文章
P Baliakas, S Jeromin, M Iskas, A Puiggros, K Plevova… - Blood, The Journal of the American Society of …, 2019